Market Snapshot
S&P Futures
4,132.25
Dow Futures
32,794
Nasdaq Futures
13,101.5
Ovid Therapeutics Inc. (OVID) stock declined over - intraday to trade at $2.2 a share on NASDAQ. The stock opened with a gain of 1.38% at $2.18 and touched an intraday high of $2.22, falling -0.00% against the last close of $2.2. The stock went to a low of $2.17 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-08-08 | $2.18 | $2.22 | $2.17 | $2.2 | 30,650 |
2022-08-05 | $2.17 | $2.21 | $2.17 | $2.2 | 35,700 |
2022-08-04 | $2.2 | $2.22 | $2.16 | $2.2 | 26,600 |
2022-08-03 | $2.2 | $2.285 | $2.155 | $2.22 | 329,400 |
2022-08-02 | $2.093 | $2.2 | $2.05 | $2.2 | 221,500 |
2022-08-01 | $2.01 | $2.11 | $1.99 | $2.08 | 57,500 |
2022-07-29 | $1.96 | $2.1 | $1.93 | $2.05 | 68,600 |
2022-07-28 | $2.06 | $2.07 | $1.97 | $1.99 | 37,300 |
2022-07-27 | $2.08 | $2.1 | $2.025 | $2.07 | 36,500 |
2022-07-26 | $2.03 | $2.07 | $2.01 | $2.02 | 42,400 |
Employees-
Beta1.24
Sales or Revenue1.45 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Ovid Therapeutics Inc. (NASDAQ: OVID) stock price is $2.2 as of the last check on Monday, August 8. During the trading session, OVID stock reached the peak price of $2.22 while $2.17 was the lowest point it dropped to.
The NASDAQ listed OVID is part of Biotechnology industry that operates in the broader Health Care sector. Ovid Therapeutics Inc. , a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir
Pres, CEO & Chairman
Mr. Jeffrey A. Rona
Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer
Mr. Thomas Michael Perone J.D., M.B.A.
Gen. Counsel, Chief Compliance Officer & Corp. Sec.
Dr. Matthew J. During Ph.D., M.D., DSc, FACP, FRACP
Founder & Member of Scientific Advisory Board
OVID stock traded closed the last session at $2.2, which is $0 or 0% lower than its previous close of $2.2. OVID's current trading price is 33.33% lower than its 52-week high of $4.2 where as its distance from 52-week low of 1.65% is -47.62%.
Number of OVID employees currently stands at -. OVID operates from 1460 Broadway, Suite 15021, New York, NY 10036, United States.
Official Webiste of $OVID is: https://www.ovidrx.com
OVID could be contacted at OVID operates from 1460 Broadway, Suite 15021, New York, NY 10036, United States, or at phone #646 661 7661 and can also be accessed through its website.
OVID stock volume for the day was 31,153 shares while in the previous session number of OVID shares traded was 30,650 . The average number of OVID shares traded daily for last 3 months was 180.85 Thousands.
The percentage change in OVID stock occurred in the recent session was 0% while the dollar amount for the price change in OVID stock was $0.
In the recent session, the day high for OVID stock was $2.22 while the low for OVID stock touched on the day was $2.17.
The market value of OVID currently stands at 154.9 Million with its latest stock price at $2.2 and 70.35 Million of its shares outstanding.